Foscarnet salvage therapy efficacy is associated with the presence of thymidine-associated mutations (TAMs) in HIV-infected patients

详细信息    查看全文

• 作者：Charlotte Charpentier ; Didier Laureillard ; Mustapha Sodqi ; Ali Si-Mohamed ; Marina Karmochkine ; Laurent Bé ; lec ; Laurence Weiss ; Christophe Piketty
• 刊名：Journal of Clinical Virology
• 出版年：2008
• 出版时间：October 2008
• 年：2008
• 卷：43
• 期：2
• 页码：212-215
• 全文大小：254 K

文摘

Background

Salvage therapy based on foscarnet plus a thymidine analog is effective in patients with advanced-stage HIV disease and viruses harbouring multiple drug-resistance mutations.

Objective

To identify viral genetic determinants associated with the virological efficacy of foscarnet salvage therapy.

Study design

Thirteen patients received foscarnet at a fixed dose of 80 mg/kg twice daily for 14 days, in combination with zidovudine or stavudine.

Results

The baseline median HIV viral load and CD4 cell count were 5.10 log₁₀ copies/ml and 23 cells/mm³, respectively. Following foscarnet therapy, viral load fell by a median of 1.84 log₁₀ copies/ml (range: −0.29 to −2.82), and by at least 1 log₁₀ copies/ml in 11 patients, all of whom harboured viruses with at least three thymidine-associated mutations (TAMs). The two patients with smaller declines in viral load (<0.50 log₁₀ copies/ml) harboured viruses with only one or zero TAMs.

Conclusions

These findings corroborate, in vivo, the impact of TAMs on HIV susceptibility to foscarnet. The virological response to foscarnet salvage therapy in multiclass-experienced patients may thus differ according to the number of TAMs.